<table width="90%" border="0" cellspacing="0" cellpadding="0" align="center">
    <tbody>
        <tr>
            <td height="20" style="font-size: 0; line-height: 0"></td>
        </tr>
        <tr>
            <td valign="top"
                style="font-family:arial,helvetica,sans-serif; font-size:16px; line-height:1.2; mso-line-height-alt:120%; mso-line-height-rule:exactly; color: #595757;">
                Dear Dr. {{accFname}} {{accLname}},</td>
        </tr>
        <tr>
            <td height="20" style="font-size: 0; line-height: 0"></td>
        </tr>
        <tr>
            <td valign="top"
                style="font-family:arial,helvetica,sans-serif; font-size:16px; line-height:1.4; mso-line-height-alt:120%; mso-line-height-rule:exactly; color: #595757;">
                In everyday practice, <strong>T2DM patients</strong> often present with <strong>complex
                    profiles</strong> that <strong>differ from populations</strong>
                studied in <strong>RCTs.</strong><sup>1</sup> Thus, <strong>RWE studies</strong> are essential to
                <strong>complement RCT data.<sup style="line-height: 1; font-size: 70%;">2</sup></strong>
            </td>
        </tr>
        <tr>
            <td height="20" style="font-size: 0; line-height: 0"></td>
        </tr>
        <tr>
            <td valign="top"
                style="font-family:arial,helvetica,sans-serif; font-size:16px; line-height:1.4; mso-line-height-alt:120%; mso-line-height-rule:exactly; color: #595757;">
                Across multiple international RWE studies, <strong>Vildagliptin (Galvus®)</strong> and <strong>Vildagliptin + Metformin
                (Galvus®Met)</strong> consistently demonstrated <strong>good treatment response</strong> without tolerability issues, confirming
                their value as part of routine care in clinical practices around the world.<sup>2-5</sup>
            </td>
        </tr>
        <tr>
            <td height="20"></td>
        </tr>
    </tbody>
</table>